Performance evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals

•Finecare fluorescence lateral flow immunoassay (LFIA) test quantitatively detects SARS-CoV-2 spike protein receptor-binding domain (S-RBD) total antibodies.•Finecare test showed 92% sensitivity and 100% specificity.•Finecare test strongly correlates with surrogate virus-neutralizing test (sVNT) and automated assays.•Finecare test can be used to predict the amount of neutralizing antibodies.